Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mechel reported for 2023 by RAS

3/29/24 MTLR

Lenta reported for 2023 by RAS

3/29/24 LENT

X5 Retail Group moves to Russia in a forced move

3/29/24 X5

Chelyabinsk Metallurgical Plant reported for 2023 by RAS

3/29/24 CHMK

Surgutneftegaz reported for 2023 by RAS

3/29/24 SNGS

Rusolovo reported for 2023 by RAS

3/29/24 ROLO

RSC Energia reported for 2023 by RAS

3/29/24 RKKE

NovaBev reported for 2023 by RAS

3/29/24 BELU

FGC-Rosseti reported for 2023 by RAS

3/29/24 FEES

FGC-Rosseti reported for 2023 by IFRS

3/29/24 FEES